<div id="readability-page-1"><div>RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501’s clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event (“SAE”); (4) accordingly, RP-A501’s safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTA4MDI2ODg2NTJyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTA4MDI2ODg2NTJyMQ"/> Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View source version on businesswire.com: https://www.businesswire.com/news/home/20250802688652/en/</div></div>

Rocket制藥

Rosen 律師事務所呼籲 Rocket Pharmaceuticals, Inc.（納斯達克代碼：RCKT）的股東，如果他們的損失超過 10 萬美元，請與他們聯繫以瞭解自己的權利。針對在 2024 年 9 月 17 日至 2025 年 5 月 26 日期間購買證券的投資者，已提起集體訴訟，指控該公司誤導投資者關於其 RP-A501 治療的有效性和安全性。希望領導該集體訴訟的股東必須在 2025 年 8 月 11 日之前提交動議。Rosen 律師事務所以風險代理費用的方式運營，確保股東無需支付前期費用

RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

RCKT 最后期限：Rosen 律师事务所敦促 Rocket 制药公司（NASDAQ: RCKT）的股东，如果损失超过 10 万美元，请联系该事务所以了解他们的权利信息